Ken Griffin Elevation Oncology, Inc. Call Options Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
Call Options
2 transactions
Others Institutions Holding ELEV
# of Institutions
71Shares Held
39.1MCall Options Held
100Put Options Held
3.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.66 Million0.21% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.9 Million0.21% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.15 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA2.97MShares$1.81 Million0.06% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.73 Million0.6% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $14.2M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...